Endothelial Cell Line to Study Prevention of Atherosclerosis

Atherosclerosis underlies most cases of cardiovascular disease (CVD), which is now the major cause of morbidity and mortality in developed countries. An inflammatory reaction is an essential component in the appearance and development of an atherosclerotic lesion. The inflammatory process is associated with the expression of adhesion molecules such as vascular cell adhesion molecule (VCAM) at the surface of endothelial cells. Antiatherogenic lipoprotein, high density lipoprotein (HDL), is known to down regulate the expression of VCAM. Increasing levels of HDL is a promising way to reduce the risk of CVD.

This technology is directed to the generation of a stable endothelial cell line expressing a luciferase reporter construct driven by the VCAM promoter. This reporter system enables an easier measurement of VCAM expression and determination of the effect of HDL on endothelial cell inflammation. This technology can be used to screen for the effect of drugs that modulate HDL metabolism and it is more convenient than doing Western blots.

Potential Commercial Applications: Competitive Advantages:
  • Study of prevention of atherosclerosis
  • Screen serum for the effect of HDL on endothelial cell inflammation
  • Screen for the effect of drugs that modulate HDL metabolism
  • Easy monitoring of down regulation of VCAM with luciferase
  • More convenient than doing Western blots

Development Stage:
In vitro data available


Alan Remaley (NHLBI)  ➽ more inventions...

Intellectual Property:
Research Tool — Patent protection is not being pursued for this technology.

D'Souza W, et al. PMID 20508181

Collaboration Opportunity:

The Cardiovascular & Pulmonary Branch, NHLBI/NIH, is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize endothelial cells to study prevention of atherosclerosis. For collaboration opportunities, please contact Dr. Alan Remaley at aremaley1@cc.nih.gov.

Licensing Contact:
Michael Shmilovich, J.D.
Email: shmilovm@mail.nih.gov
Phone: 301-435-5019

OTT Reference No: E-149-2012-0
Updated: Jun 13, 2012